Medifast

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm’s product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medifast reports Q4 revenue decline, focuses on cost management

Medifast's Q4 2022 performance saw revenue decline but strong cost management and cash generation.
Challenges include revenue outlook for Q1 2023 and competitive landscape in weight loss and coaching markets.
Opportunities lie in capital allocation strategies, maintaining shareholder value, and adapting to market trends.
Overall, Medifast remains focused on long-term growth, financial stability, and delivering on its mission.

Medifast surpasses Q1 expectations, eyes growth amid operational tweaks

Medifast's Q1 2023 performance exceeded expectations, with a focus on revenue growth and cost control measures.
Despite challenges like decreased active coaches, the company is well-positioned with a strong financial standing and growth initiatives.
Opportunities in customer acquisition, cost-saving efforts, market expansion, and innovative solutions pave the way for future success.
Guidance for Q2 2023 reflects a strategic approach to balancing growth and profitability amidst market dynamics and operational changes.

Medifast reports Q2 revenue decline, eyes sustainable growth strategies

Medifast navigated challenges in Q2 2023 with improved operating margin and strategic market exits.
The company's focus on new growth initiatives and cost-saving measures reflects adaptability to market dynamics.
While facing revenue declines and competitive pressures, Medifast aims for sustainable growth with clear targets.
Exploration of medically supported weight loss solutions and new product lines offer avenues for future expansion.

Medifast reports resilient Q3 performance, eyes growth through diversification

Medifast's Q3 performance reflects resilience amid revenue decline, with a focus on operational efficiency and financial strength. While facing challenges in revenue and expense management, the company remains agile and proactive in exploring growth opportunities through market expansion and social responsibility initiatives.

Medifast transitions to health and wellness focus amidst revenue challenges

Medifast is navigating challenges in customer acquisition and macro factors while focusing on becoming a diversified health and wellness company.
The company's strategic collaboration with Life MD and new product offerings position it for growth.
While Q4 2023 saw a revenue decrease, Medifast's improved gross profit margin and cost-saving initiatives demonstrate operational efficiency.
Investors should monitor the impact of increased marketing spending on operating margin and EPS in the coming years.

Medifast faces revenue decline due to weight loss medication trends

Medifast's Q1 2024 performance reflects challenges in revenue and income, driven by difficulties in customer acquisition amidst weight loss medication trends.
Despite the decline, the company demonstrated operational efficiency with improved gross profit margins and cost management.
Investments in marketing and collaborations present opportunities for future growth and market expansion, signaling a strategic focus on long-term success.
Navigating market challenges while capitalizing on opportunities will be crucial for Medifast's resilience and competitiveness in the weight loss industry.

Medifast reports Q2 losses, focuses on growth strategies and cost management

Medifast's Q2 2024 performance reflects a challenging period marked by revenue and profit declines, offset by margin improvements and cost reductions.
The company's strategic initiatives aim to drive long-term growth and enhance operational efficiency amidst macroeconomic headwinds and lower coach productivity.
While facing financial setbacks, Medifast's focus on targeted advertising, product diversification, and cost management signifies a proactive stance towards future recovery and growth.

Medifast adapts to industry changes with tailored programs and innovations

Medifast's Q3 2024 performance reflected revenue and net income declines, highlighting challenges in the weight loss industry.
Despite these challenges, the company's strategic focus on tailored programs, strong financial position, and new product launches indicate a proactive approach to addressing market dynamics.
Opportunities in clinical studies, new product launches, and financial strength position Medifast for potential growth and market expansion in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm's product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

NEW YORK, NY / ACCESSWIRE / August 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medifast, Inc. ("Medifast") (NYSE:MED) concerning possible violations of federal securities laws. Medifast reported its quarterly earnings on April 29, 2024.

An Investigation Has Commenced on Behalf of Medifast, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your MED Losses.

LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Has Launched An Inquiry Into Medifast Inc And The Firm Is Seeking Investors To Participate

NEW YORK, NY / ACCESSWIRE / August 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medifast, Inc. ("Medifast") (NYSE:MED) concerning possible violations of federal securities laws. Medifast reported its quarterly earnings on April 29, 2024.

MED ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Medifast, Inc. investment

LOS ANGELES, CA / ACCESSWIRE / August 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

A Securities Fraud Investigation Of Medifast Inc Has Been Opened By The Schall Law Firm And Stockholders Are Urged To Reach Out

NEW YORK, NY / ACCESSWIRE / August 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medifast, Inc. ("Medifast") (NYSE:MED) concerning possible violations of federal securities laws. Medifast reported its quarterly earnings on April 29, 2024.

Medifast, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Medifast (MED)

LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Inquiring Into Medifast Inc. For Potential Securities Law Violations And Impacted Investors Are Encouraged To Participate

LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medifast Inc. Is Being Investigated By The Schall Law Firm For Possible Securities Fraud And Affected Shareholders Are Invited To Join

NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medifast, Inc. ("Medifast") (NYSE:MED) concerning possible violations of federal securities laws. Medifast reported its quarterly earnings on April 29, 2024.

Medifast, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - MED

LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Medifast Inc. For Potential Securities Law Violations And Encourages Investors To Reach Out

NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medifast, Inc. ("Medifast") (NYSE:MED) concerning possible violations of federal securities laws. Medifast reported its quarterly earnings on April 29, 2024.

Lost Money on Medifast, Inc. (MED)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating Medifast Inc. For Possible Securities Fraud And Invites Shareholders To Help

NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medifast, Inc. ("Medifast") (NYSE:MED) concerning possible violations of federal securities laws. Medifast reported its quarterly earnings on April 29, 2024.

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Medifast, Inc. (MED)

LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Claims Against Medifast, Inc. For Securities Fraud And Seeks Investor Involvement

NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medifast, Inc. ("Medifast") (NYSE:MED) concerning possible violations of federal securities laws. Medifast reported its quarterly earnings on April 29, 2024.

Shareholders that lost money on Medifast, Inc.(MED) should contact Levi & Korsinsky about Securities Fraud Investigation - MED

LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Inquiring Into Claims Against Medifast, Inc. And Invites Shareholder Participation

LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating Claims Against Medifast, Inc. And Urges Investor Participation

NEW YORK, NY / ACCESSWIRE / August 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medifast, Inc. ("Medifast") (NYSE:MED) concerning possible violations of federal securities laws. Medifast reported its quarterly earnings on April 29, 2024.

Did Medifast, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - MED

LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating Medifast, Inc. And Seeks Investor Participation

Shareholders That Lost Money on Medifast, Inc. (MED) Should Contact Levi & Korsinsky About Securities Fraud Investigation - MED

LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Opening An Investigation Into Medifast, Inc. And Encourages Investor Participation

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Announces An Investigation Into Claims Against Medifast, Inc. And Invites Investor Participation

Medifast (MED) is encountering difficulties in attracting customers due to a reduction in the number of active OPTAVIA Coaches and diminished productivity per Coach.

Medifast (MED) Tumbles 25% in 3 Months: Should You Buy Now?

Medifast's (MED) Q2 results highlight the challenges of poor customer acquisition. However, the company is focusing strategically on medically supported weight loss, indicating potential for growth.

Medifast (MED) Q2 Earnings Beat Estimates, Revenues Fall Y/Y

Medifast, Inc. (NYSE:MED ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Steven Zenker - Vice President, Investor Relations Dan Chard - Chairman and Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants James Salera - Stephens Linda Bolton-Weiser - D.A. Davidson David Larsen - BTIG Operator And welcome to the Medifast Second Quarter 2024 Earnings Conference Call.

Medifast, Inc. (MED) Q2 2024 Earnings Call Transcript

Medifast (MED) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $2.77 per share a year ago.

News for Medifast Stock (MED)